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Dear Editor, 40 
Multidrug-resistant tuberculosis (MDR-TB; defined by bacillary resistance against rifampicin 41 
and isoniazid) has been identified as a global threat to mankind [1]. According to the latest 42 
report by the European Centres of Disease Prevention and Control and World Health 43 
Organization regional office for Europe only approximately 50% of MDR-TB patients in 44 
Europe reach favorable treatment outcomes [2]. Successful treatment outcomes are 45 
achieved for less than 25% of patients with extensively drug-resistant TB (XDR-TB; MDR plus 46 
resistance against a least one fluoroquinolone and one second-line injectable drug) in the 47 
European Union/European Economic Area Countries [2]. 48 
Recently, new diagnostic methods and novel drugs have been introduced that may improve 49 
treatment outcomes in countries, where these innovations are available to provide 50 
personalized therapies [3-6]. In order to evaluate treatment outcomes in M/XDR-TB under 51 
unrestricted health-care conditions, and to ascertain the difference to the treatment 52 
outcome in patients with drug-susceptible TB, we performed a multicenter prospective 53 
observational cohort study in patients with M/XDR- and non-M/XDR-TB at clinical centers in 54 
Germany. We also sought to compare existing WHO and newly described “simplified” 55 
therapy outcome definitions for both M/XDR- and non-M/XDR-TB patients [7, 8]. 56 
Patients with pulmonary TB confirmed by the GeneXpert MTB/RIF test (Cepheid, Sunnyvale, 57 
USA) were enrolled at five hospitals in Germany (Medical Clinic, Research Center Borstel; 58 
Karl-Hansen-Klinik, Bad Lippspringe; Sankt Katharinen-Krankenhaus, Frankfurt; Thoraxklinik-59 
Heidelberg, Heidelberg; Asklepios Fachkliniken München-Gauting, Munich) between March 60 
2013 and March 2016. Patients less than 18 years of age and/or HIV-positive, or individuals 61 
under legal supervision were excluded from the study. Written informed consent was 62 
obtained from all patients. 63 
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Samples with a positive GeneXpert result for rifampicin resistance were further analyzed by 64 
using line-probe-assays (Hain Lifesciences, Nehren, Germany) for the detection of additional 65 
first- and second-line drug-resistances. Findings were later confirmed by culture based drug 66 
susceptibility tests (DST) at the national reference center for mycobacteria in Borstel, 67 
Germany. Individualized anti-TB drug regimens for patients with M/XDR-TB were designed 68 
using current therapy recommendations on the basis of molecular and phenotypic DST [9, 69 
10]. The algorithms were in main consent with the current WHO guidelines [11]. However, 70 
the preferred usage of certain drugs changed over time (i.e. linezolid). Patients with non-71 
M/XDR-TB were treated following national recommendations [12]. In addition to WHO-72 
defined outcome definitions [8], we applied simplified outcome definitions that include a 73 
one-year follow-up to both patient groups. According to the simplified outcome definitions 74 
[7]: 75 
Cure is defined as a negative culture status six months after treatment initiation, no positive 76 
culture thereafter, and no relapses within one year after treatment completion.  77 
Treatment failure is defined as a positive culture status six months after treatment initiation 78 
or thereafter or a relapse within 1 year after treatment completion.  79 
Undeclared outcome is defined as an outcome that was not assessed (owing to transferal 80 
out of the cohort, no culture status at six months while the patient was receiving care, or no 81 
post-treatment assessment).  82 
Death is defined as death during observation.  83 
Loss to follow-up is defined as non-receipt of care six months after treatment initiation.  84 
For the follow-up one-year after therapy end, patients were contacted by telephone 85 
interviews or/and during routine clinical follow-up visits. 86 
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Study approval was granted by the Ethics Committee of the University of Lübeck (AZ 12-233), 87 
which subsequently was confirmed by the corresponding local Ethic Committees of all 88 
participating centers. Statistic analyses were performed using STATA (Version 14, StataCorp 89 
LLC, College Station, Texas, USA). 90 
 91 
Seventy-five patients were enrolled, of whom 46 were infected with non-M/XDR and 29 with 92 
MDR strains of M. tuberculosis. Of the 29 patients with M/XDR-TB, eight patients were 93 
infected with an XDR strain of M. tuberculosis. In the cohort of non-M/XDR-TB patients, two 94 
patients had isoniazid mono-resistant TB. Only 3/29 (10.4%) M/XDR-TB patients received an 95 
anti-TB regimen containing bedaquiline or delamanid, which became available during the 96 
study period. Of the 22/29 (75.9%) M/XDR-TB patients receiving fluoroquinolones 18/22 97 
(81.8%) were treated with moxifloxacin while 4/22 (18.2%) received levofloxacin. Twenty-98 
one of 29 (72.4%) M/XDR-TB patients were administered second-line injectable drugs, of 99 
whom 14/21 (66.7%) patients received capreomycin and 7/21 (33.3%) amikacin. 100 
Patients with M/XDR- and non-M/XDR-TB showed similar frequencies of relapse-free cure 101 
(65.5% and 63.0%, respectively, p = 0.828), as they did for death and failure (Figure). Just 102 
eight patients (three M/XDR-TB, five non-M/XDR-TB) achieved cure by WHO-definitions. 103 
Treatment success by WHO definition, driven by treatment completion, was markedly lower 104 
for M/XDR-TB patients (58.6%) compared to non-M/XDR-TB patients (76.1%, p = 0.110). 105 
Given the relatively low number of patients, we did not identify any specific properties that 106 
characterize patients with therapy failure (Simplified outcomes: non-M/XDR-TB n=7 vs. 107 
M/XDR-TB n=3). 108 
 109 
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Under optimal management conditions and resources we observed similar frequencies of 110 
relapse-free cure in patients with M/XDR-TB and non-M/XDR-TB when applying outcome 111 
definitions that include a one-year follow-up period after the completion of treatment [7]. 112 
The lack of marked differences in treatment response between the two groups using new 113 
definitions is encouraging and stands in sharp contrast to the low frequency of WHO-defined 114 
cure for patients with TB ascertained on the last day of treatment. Frequency of treatment 115 
success by WHO definition (the sum of those who achieve cure or complete their treatment 116 
in the absence of failure) is nearly identical to the estimates reported by the European 117 
Centre for Disease Prevention and Control (ECDC) surveillance data (2). A recent multi-118 
national observational cohort study in Europe showed that WHO-defined treatment success 119 
is largely based on treatment completion rather than on cure [7, 8]. This was confirmed in 120 
the present study where only 6.5% of patients with non-M/XDR-TB were cured and 69.6% of 121 
patients had treatment completion. The main reason for the absence of cure is lack of the 122 
required number of sputum samples in the final stage of treatment. 123 
Prevention of relapse is the main purpose for the long duration of therapy in TB. Thus, cure 124 
from TB’s definition should include a relapse-free observation period after the end of 125 
therapy, which is already the case in anti-TB drug trials [13]. In the field of oncology, which is 126 
similar in this aspect to TB, determining cure (corresponding to end points such as 127 
progression free survival) at the last day of chemotherapy would be inacceptable [14]. As the 128 
majority of the relapse cases occur within twelve months of treatment completion, an 129 
observation period of one year is plausible to define relapse-free cure as it was recently 130 
proposed [7, 13]. A negative M. tuberculosis culture status at six-months of treatment, as the 131 
critical assessment point for the simplified definitions, has been shown to be predictive for 132 
cure in MDR-TB [7, 15]. The current study shows that applying the same outcome definitions 133 
for patients with non-M/XDR-TB and M/XDR-TB gives plausible results in line with clinical 134 
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experience. This opens the door to adopt a single set of outcome definitions for all 135 
pulmonary TB patient, regardless of resistance pattern or duration of therapy. Such a move 136 
will simplify and improve outcome reporting. 137 
Recently, two groups have demonstrated six-months culture conversion rates of 96% [16] 138 
and 100% [17] in patients with M/XDR-TB treated with bedaquiline-based regimens 139 
providing hope that much higher cure-rates from M/XDR-TB can be achieved in the future.  140 
 141 
In conclusion, in a country where sufficient resources for the management of patients with 142 
M/XDR-TB are available, we now observe substantial improvements in treatment outcomes 143 
resulting in a high frequency of relapse-free cure indistinguishable from cure in patients with 144 
non-M/XDR-TB. This “honeymoon” may last until strains of M. tuberculosis that have 145 
developed resistance against novel and refurbished second-line drugs start circulating in the 146 
community. WHO treatment outcome definitions for TB should be revised to describe cure 147 
only in the in the absence of disease recurrence one year after the end of treatment. 148 
 149 
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Figure 155 
 156 
 157 
Figure. Treatment outcomes for patients with non-M/XDR-TB and M/XDR-TB by simplified 158 
(TBNET) definitions (a) and WHO definitions (b). The simplified outcomes yielded the 159 
following results: Death: non-M/XDR-TB n=3 (6.5%) vs. M/XDR-TB n=2 (6.9%); Lost to follow-160 
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up: non-M/XDR-TB n=5 (10.9%) vs. M/XDR-TB n=4 (13.8%); Failure: non-M/XDR-TB n=7 161 
(15.2%) vs. M/XDR-TB n=3 (10.3%); Cure: non-M/XDR-TB n=29 (63.0%) vs. M/XDR-TB n=19 162 
(65.5%); Undeclared: non-M/XDR-TB n=2 (4.4%) vs. M/XDR-TB n=1 (3.5%). Outcomes 163 
following the WHO’definitions were: Death: non-M/XDR-TB n= 3 (6.5%) vs. M/XDR-TB n=2 164 
(6.9%); Lost to follow-up: non-M/XDR-TB n=5 (10.9%) vs. M/XDR-TB n=5 (17.2%); Failure: 165 
non-M/XDR-TB n=1 (2.2%) vs. M/XDR-TB n=5 (17.2%); Cure non-M/XDR-TB n=3 (6.5%) vs. 166 
M/XDR-TB n=5 (17.2%); Completed non-M/XDR-TB n=32 (69.6%) vs. M/XDR-TB n=12 167 
(41.4%); Not evaluated non-M/XDR-TB n=2 (4.4%) vs. M/XDR-TB n=0 (0.0%). Total for both 168 
analysis: non-M/XDR-TB n=46 (100%) vs. M/XDR-TB n=29 (100%). 169 
  170 
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